ML21279A236

From kanterella
Jump to navigation Jump to search
Export License Issued to Cambridge Isotope Laboratories, Inc. XMAT448-03
ML21279A236
Person / Time
Site: 11006349
Issue date: 10/06/2021
From: David Skeen
NRC/OIP
To: Dabkowski R
Cambridge Isotope Labs
Savoy J
References
Download: ML21279A236 (16)
v • d • e


Text

NRC FORM250 EXPORT LICENSE United States of America Nuclear Regulatory Commission Washington, D.C. 20555 NRC LICENSE NO.: XMAT448/03 Page 1 of 16 NRC DOCKET NO.: 11006349 LICENSE EXPIRES: December 6, 2021 Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

LICENSEE Cambridge Isotope Laboratories, Inc.

50 Fontage Road ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)

See following page(s)

Andover, MA 01810 Attn: Rebecca Dabkowski INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)

OTHER U.S. PARTY(IES) TO EXPORT See following page(s)

See following page(s)

APPLICANTS

REFERENCE:

XMAT448 ULTIMATE DESTINATIONS: India and France QUANTITY(IES)

DESCRIPTION OF MATERIAL($) OR FACILITY(IES)

This license is amended to: 1) include additional Ultimate Foreign Consignee(s); 2) revising the names of Ultimate Foreign Consignee(s); 3) revise the date of expiration from May 31, 2025 to December 6, 2021; and 4) update the addresses to Other U.S. Parties to Export.

The license is authorized to export a cumulative total 10,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds.

The cumulative total starts from the issuance of the original license XMAT448.

Neither this license nor any right under this license shall be THIS LICENSE IS INVALID UNLESS SIGNED BELOW assigned or otherwise transferred in violation of the BY AUTHORIZED NRC REPRESENTATIVE provisions of the Atomic Energy Act of

1954, as amended, and the Energy Reorganization Act of 1974.

SIGNATURE:

This license is subject to the right of recapture or control NAME AND TITLE:

by Section 108 of the Atomic Energy Act of 1954, as David L. Skeen, Deputy Director Office of International Programs amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of DATE OF ISSUANCE: _____________ _

the NRC.

EXPORT LICENSE David Skeen Digitally signed by David Skeen Date: 2021.10.06 09:26:43

-04'00' October 6, 2021

ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

2.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

3.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

4.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

5.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

6.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

7.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

8.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 2 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

9.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

10.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

11.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

12.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

13.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

14.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

15.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

16.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 3 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

17.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

18.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

19.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

20.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

21.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

22.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

23.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

24.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 4 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

25.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

26.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

27.

n,a (for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

28.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

29.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

30.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

31.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

32.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 5 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

33.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

34.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

35.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

36.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

37.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

38.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

39.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

40.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 6 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

41.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

42.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

43.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

44.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

45.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

46.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

47.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

48.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 7 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

49.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

50.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

51.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

52.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

53.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

54.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

55.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

56.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 8 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

57.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

58.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

59.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

60.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

61.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

62.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

63.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

64.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 9 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

65.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

66.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

67.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

68.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

69.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

70.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

71.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

72.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 10 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

73.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

74.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

75.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

76.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

77.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

78.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

79.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

80.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 11 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

81.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

82.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

83.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

84.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

85.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

86.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

87.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

88.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 12 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

89.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

90.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

91.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

92.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

93.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

94.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

95.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

96.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 13 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

97.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

98.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

99.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) 100.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) 101.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) 102.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) 103.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) 104.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT448/03 Page 14 of 16

ULTIMATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

105.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) 106.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) 107.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) 108.

n,a (for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

INTERMEDIATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

1.

(for distribution to ultimate consignees)

2.

(for distribution to ultimate consignees)

3.

(for distribution to ultimate consignees)

4.

(for distribution to ultimate consignees)

XMAT448/03 Page 15 of 16

INTERMEDIATE CONSIGNEE($) IN FOREIGN COUNTRY(IES):

5.

(for distribution to ultimate consignees)

6.

(for distribution to ultimate consignees)

7.

(for distribution to ultimate consignees)

8.

(for distribution to ultimate consignees)

9.

(for distribution to ultimate consignees)

10.

(for distribution to ultimate consignees)

OTHER U.S. PARTY(IES) TO EXPORT:

1 _ Cambridge Isotope Laboratories, Inc.

6 Highwood Drive Tewksbury, MA 01876 (supplier)

2. Cambridge Isotope Laboratories, Inc.

50 Frontage Road Andover, MA 01810 (supplier/distributors)

3. Cambridge Isotope Separations 1689 Burnett Drive Xenia, OH 45385 (supplier)

XMAT448/03 Page 16 of 16

Retrieved from "https://kanterella.com/w/index.php?title=ML21279A236&oldid=3808165"